GlassScriptPhysician profile
Brianna E Kay
NPI 1356784243
$5,731.66
in general payments reported to CMS, 2019-2025
25 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,393 · 2022: $757 · 2023: $961 · 2024: $924 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,977 · Education: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,976.77 |
| Education | $604.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,520.84 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $744.84 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $401.30 | 2021-2025 | Dupixent |
| Abbvie INC. | $377.08 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $340.20 | 2021-2025 | Tremfya |
| Ucb, INC. | $335.97 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $316.71 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Sun Pharmaceutical Industries INC. | $304.00 | 2021-2025 | |
| Revance Therapeutics, INC. | $288.39 | 2024-2025 | Daxi |
| Novartis Pharmaceuticals Corporation | $198.19 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $161.94 | 2021-2025 | |
| Medtronic, INC. | $147.72 | 2021 | |
| Genzyme Corporation | $126.79 | 2021-2025 | |
| Dermavant Sciences, INC. | $124.99 | 2023 | Vtama |
| Merck Sharp & Dohme LLC | $78.48 | 2023 | Verquvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $57.52 | 2023-2024 | Opzelura |
| Pfizer INC. | $42.92 | 2021 | |
| Eli Lilly and Company | $31.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.31 | 2023 | Sotyktu |
| Organon LLC | $20.05 | 2025 | Vtama |
| Amgen INC. | $18.82 | 2025 | Otezla |
| Botanix Sb INC | $17.32 | 2025 | Sofdra |
| Genentech USA, INC. | $16.59 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.80 | 2024 | Jublia |
| Strata Skin Sciences, INC. | $15.22 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.